{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-038020","form_type":"8-K","ticker":"ETON","cik":"0001710340","company_name":"Eton Pharmaceuticals, Inc.","filed_at":"2024-12-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.306574+00:00","generated_at":"2026-05-29T00:20:37.902528+00:00","sec_items":["2.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Eton Pharma closes $22.5M Increlex acquisition; expands credit facility","bullets":["Acquired Increlex (mecasermin) from Ipsen for $22.5M at closing plus $8.7M inventory; $2.5M due on first and second anniversaries.","Credit facility with SWK expanded by $25.7M to $30M, maturity to 3 years, SOFR+6.75%; warrant for 289,736 shares at $5.32 issued.","Increlex is the only FDA/EMA approved treatment for severe primary IGF-1 deficiency in pediatric patients aged 2+.","U.S. available via AnovoRx specialty pharmacy; Eton to commercialize outside U.S. after 6-month transition.","Additional inventory purchase obligation up to EUR 15.0 million over 30 months; transaction financed by cash and credit."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-038020","json":"https://secwatch.observer/filing/0001437749-24-038020.json","markdown":"https://secwatch.observer/filing/0001437749-24-038020.md","text":"https://secwatch.observer/filing/0001437749-24-038020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710340/000143774924038020/0001437749-24-038020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710340/000143774924038020/eton20241215_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T00:20:37.902528+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}